JNJ10191584 (VUF6002) is an orally active and selective histamineH₄receptorantagonist with aK_ivalue of 26 nM. JNJ10191584 shows 540-fold selectivity toH₄receptoroverH₃receptorwith aK_ivalue of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells withIC₅₀values of 530 nM and 138 nM, respectively^[1][2].

JNJ10191584 shows binding affinity of 26 nM and 14.1 μM to H₄and H₃receptor, respectively^[1].
JNJ10191584 (3 h) shows inhibitory effects to chemotaxis of eosinophils and mast cells with IC₅₀values of 530 nM and 138 nM, respectively^[1].

JNJ10191584 (10 μg/μL; intra locus coeruleus (LC) administration; once) abolishs VUF-induced anti-allodynic effect in spared nerve injury (SNI) mice^[1].
JNJ10191584 (10 μg/μL; intra LC administration; once) prevents the anti-allodynic effect of VUF 8430 in SNI mice^[1].
JNJ10191584 (6 μg/mouse; intrathecal administration; pretreat once) prevents VUF 8430-induced anti-allodynic effect in SNI mice^[1].

278.74

C₁₃H₁₅ClN₄O

73903-17-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.